Chemometec A/S
CSE:CHEMM
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| DK |
|
Chemometec A/S
CSE:CHEMM
|
7.1B DKK |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
990.7B USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
179B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
131.7B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
33.6B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
265.7B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
31.6B USD |
Loading...
|
|
| US |
|
Waters Corp
NYSE:WAT
|
27.8B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27.6B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
23.8B USD |
Loading...
|
Market Distribution
| Min | -2 199.8% |
| 30th Percentile | 26.7% |
| Median | 45.7% |
| 70th Percentile | 65.9% |
| Max | 1 637.7% |
Other Profitability Ratios
Chemometec A/S
Glance View
Chemometec A/S, a Danish firm founded in the late 1990s, has carved a niche in the specialized world of biotech instrumentation. The company is renowned for developing and manufacturing high-precision cell counting and analysis instruments used predominantly in the life sciences sector. Its flagship product, the NucleoCounter®, has gained significant traction in laboratories and production facilities worldwide. This product stands out due to its accuracy and ease of use in counting various types of cells, whether in research or pharmaceutical production settings. Unlike traditional methods, Chemometec’s technology enables researchers to save time and reduce error, which is invaluable for laboratories looking to enhance their workflow efficiencies. Revenue for Chemometec is primarily generated through the sale of its advanced instruments and associated consumables, along with providing expert services that support the integration and maintenance of these technologies. The company's business model capitalizes on the growing global demand for sophisticated biomedical research tools, as innovation in the drug development and biotechnology sectors accelerates. By continuously investing in R&D, Chemometec not only ensures its products remain cutting-edge but also expands its applicability across new areas in the life sciences field. The strategy of maintaining close relationships with its end-users ensures that as the scientific landscape evolves, Chemometec is well-positioned to adapt and grow.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Chemometec A/S is 83.8%, which is above its 3-year median of 80.6%.
Over the last 3 years, Chemometec A/S’s Gross Margin has increased from 80.2% to 83.8%. During this period, it reached a low of 78.8% on Jun 30, 2024 and a high of 83.8% on Jan 1, 2026.